Matthew Stober
Vorstandsvorsitzender bei ABZENA PLC
Aktive Positionen von Matthew Stober
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ABZENA PLC | Direktor/Vorstandsmitglied | 12.12.2022 | - |
Vorstandsvorsitzender | 12.12.2022 | - |
Karriereverlauf von Matthew Stober
Ehemalige bekannte Positionen von Matthew Stober
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CastleVax, Inc.
CastleVax, Inc. BiotechnologyHealth Technology CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre. | Vorstandsvorsitzender | - | - |
Präsident | - | - | |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Präsident | - | - | |
BIOVENTUS INC. | Direktor/Vorstandsmitglied | - | - |
SMITH & NEPHEW PLC | Geschäftsführer | 01.10.2015 | - |
JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
HOSPIRA, INC. | Geschäftsführer | 01.06.2011 | - |
Ausbildung von Matthew Stober
Villanova University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Vereinigtes Königreich | 3 |
Operativ
Director/Board Member | 3 |
Chief Executive Officer | 3 |
Chief Operating Officer | 2 |
Sektoral
Health Technology | 8 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
JOHNSON & JOHNSON | Health Technology |
SMITH & NEPHEW PLC | Health Technology |
BIOVENTUS INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Hospira, Inc.
Hospira, Inc. Pharmaceuticals: MajorHealth Technology Hospira, Inc. provides injectable drugs and infusion technologies. It offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services. The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
CastleVax, Inc.
CastleVax, Inc. BiotechnologyHealth Technology CastleVax, Inc. is an American vaccine platform company based on technology developed at the Icahn School of Medicine at Mount Sinai, headquartered in an undisclosed location. The private company's platform uses a disease virus to induce the human immune system to produce neutralizing antibodies targeted at a range of emerging and pandemic viruses, including SARS-CoV-2. The technology was developed in response to the growing need for vaccine independence and pandemic response preparedness. CastleVax's leading candidate, NDV-HXP-S, is currently being tested in clinical trials in multiple countries around the world. The company was founded by Florian Krammer, Peter Palese, Adolfo García-Sastre. | Health Technology |
Abzena Ltd.
Abzena Ltd. BiotechnologyHealth Technology Abzena Ltd. engages in the provision of proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It offers antibody discover and candidate screening, immunology and immunogenicity assessment, antibody and protein engineering, bio conjugation, custom synthesis of cytotoxic payloads, reagents, and other small molecules, manufacture of payload linkers, development of manufacturing cell lines, and manufacture of biopharmaceuticals. The company was founded by Sunil Shaunak in 2001 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Matthew Stober
- Erfahrung